Literature DB >> 23979196

A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.

S S Desai1, A S Shah, K Prabhash, N A Jambhekar.   

Abstract

BACKGROUND: An in-frame fusion protein between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic large cell kinase (ALK) genes is seen in some non-small cell lung cancer (NSCLC). EML4-ALK demonstrates constitutive kinase activity. These ALK-positive lung carcinomas have been shown to respond to ALK kinase inhibitors. ALK gene rearrangement is commonly detected using fluorescent in situ hybridization (FISH). AIMS: To study the pathological features of ALK positive and negative NSCLC and evaluate the causes of uninterpretable FISH results.
MATERIALS AND METHODS: This is a retrospective, observational study. The molecular pathology records of patients on whom test for ALK had been performed in a period of 1 year (February 2012 to February 2013) were accessioned. A total 224 cases were identified. Histological features were reviewed. The in situ hybridization was performed using Vysis ALK Dual Color Break Apart Rearrangement Probe (Abbott Molecular Inc.). Signal interpretation under the fluorescent microscope was performed in accordance with College of American Pathologists guidelines.
RESULTS: Five patients showed ALK gene rearrangement, 182 were negative and 37 cases were uninterpretable. Five patients with ALK gene rearrangement had a mean age of 48 years and the male to female ratio was 2:3. In the ALK negative cases, the mean age was 54 years and male to female ratio was 3.2:1. Histologically, amongst the rearranged cases, three showed solid pattern, one showed acinar and one showed acinar with signet ring cells on histology.
CONCLUSION: The percentage of ALK gene rearrangement was 2.7% (excluding the uninterpretable cases). These ALK positive patients were relatively younger than ALK negative patients. Solid pattern on histology was associated with ALK positivity. In a quarter of the uninterpretable results, the material submitted was fixed and processed outside.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979196     DOI: 10.4103/0019-509X.117007

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  16 in total

1.  Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.

Authors:  Kumar Prabhash; Suresh H Advani; Ullas Batra; Bivas Biswas; Anuradha Chougule; Mithua Ghosh; Vamshi Krishna Muddu; T P Sahoo; Ashok K Vaid
Journal:  Adv Ther       Date:  2019-03-12       Impact factor: 3.845

2.  Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement.

Authors:  Saumya Shukla; Nuzhat Husain; Anurag Gupta; Nidhi Anand
Journal:  J Cytol       Date:  2019 Jan-Mar       Impact factor: 1.000

3.  Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.

Authors:  Rahul Kumar Pandey; Saumya Shukla; Nuzhat Husain; Mohammad Hayatul Islam; Rahat Hadi; Surya Kant Tripathi; Ashish Singhal
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

Review 4.  Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.

Authors:  Liang Fan; Yun Feng; Huanying Wan; Guochao Shi; Wenquan Niu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

5.  Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.

Authors:  Dc Doval; K Prabhash; S Patil; H Chaturvedi; C Goswami; Ak Vaid; S Desai; S Dutt; Vh Veldore; N Jambhekar; A Mehta; D Hazarika; S Azam; S Gawande; S Gupta
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

Review 6.  Lung cancer in the Indian subcontinent.

Authors:  Vanita Noronha; Rakesh Pinninti; Vijay M Patil; Amit Joshi; Kumar Prabhash
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

7.  Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset.

Authors:  Koushik Chatterjee; Raja Bhowmik; Bhargab Chattopadhyay
Journal:  South Asian J Cancer       Date:  2017 Oct-Dec

8.  Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India.

Authors:  Aditya Navile Murali; Venkatraman Radhakrishnan; Trivadi S Ganesan; Rejiv Rajendranath; Prasanth Ganesan; Ganesarajah Selvaluxmy; Rajaraman Swaminathan; Shirley Sundersingh; Arvind Krishnamurthy; Tenali Gnana Sagar
Journal:  J Glob Oncol       Date:  2017-01-11

9.  A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study.

Authors:  Vandana Rana; Praveer Ranjan; Rajat Jagani; K R Rathi; Dharmesh Kumar; Anurag Khera
Journal:  Med J Armed Forces India       Date:  2017-11-28

10.  Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung.

Authors:  Ullas Batra; Mohit Aggarwal; Parveen Jain; Pankaj Goyal; Abhishek Yadav; Udip Maheshwari; Anurag Mehta
Journal:  South Asian J Cancer       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.